| 6.43 0.54 (9.17%) | 12-05 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 8.25 | 1-year : | 9.64 |
| Resists | First : | 7.07 | Second : | 8.25 |
| Pivot price | 5.85 |
|||
| Supports | First : | 5.05 | Second : | 3.8 |
| MAs | MA(5) : | 6.39 |
MA(20) : | 5.6 |
| MA(100) : | 6.85  |
MA(250) : | 12.25 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 67.5 |
D(3) : | 74.8 |
| RSI | RSI(14): 58.8 |
|||
| 52-week | High : | 27.92 | Low : | 3.8 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ IGMS ] has closed below upper band by 22.4%. Bollinger Bands are 3.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 6.56 - 6.6 | 6.6 - 6.63 |
| Low: | 5.54 - 5.57 | 5.57 - 5.6 |
| Close: | 6.38 - 6.43 | 6.43 - 6.48 |
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non-Hodgkin's lymphoma (NHL). It is also developing IGM-8444, an IgM antibody, which is in Phase 1 clinical trials for the treatment of patients with solid cancers; and IGM-7354, an anti-PD-L1 IgM antibody for the treatment of patients with solid and hematologic malignancies; IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of patients with multiple myeloma; and IGM-2537, a bispecific T cell engaging IgM antibody targeting CD123 and CD3 proteins for the treatment of patients with acute myeloid leukemia, myelodysplastic syndromes, and acute lymphoblastic leukemia. It has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.
Tue, 05 Dec 2023
IGM Biosciences to cut 22% of workforce, shut down blood cancer programs (NASDAQ:IGMS) - Seeking Alpha
Tue, 05 Dec 2023
IGM Biosciences Announces Strategic Pipeline Prioritization and Cash Runway Extension - Yahoo Finance
Tue, 05 Dec 2023
Will IGM Biosciences Inc (IGMS) Outperform the Rest of the Stocks in the Healthcare Sector? - InvestorsObserver
Mon, 20 Nov 2023
We Think IGM Biosciences (NASDAQ:IGMS) Needs To Drive Business Growth Carefully - Simply Wall St
Sun, 19 Nov 2023
We Think IGM Biosciences (NASDAQ:IGMS) Needs To Drive Business Growth Carefully - Yahoo Finance
Thu, 16 Nov 2023
Does IGM Biosciences, Inc. (IGMS) Have the Potential to Rally 268.31% as Wall Street Analysts Expect? - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 33 (M) |
| Held by Insiders | 1.537e+007 (%) |
| Held by Institutions | 36.7 (%) |
| Shares Short | 5,330 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.4661e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -13 % |
| Return on Assets (ttm) | 115.9 % |
| Return on Equity (ttm) | -31.4 % |
| Qtrly Rev. Growth | 1.85e+006 % |
| Gross Profit (p.s.) | 0.03 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -5 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -182 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.27 |
| Dividend | 0 |
| Forward Dividend | 4.15e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|